Breaking News, Collaborations & Alliances

Santhera, Biovail Sign Drug Pact

Santhera Pharmaceuticals and Biovail Corp. have signed a license agreement for Santhera's JP-1730/fipamezole, granting Biovail U.S. and Canadian rights to develop and commercialize the drug for the treatment of dyskinesia in Parkinson's Disease.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Santhera Pharmaceuticals and Biovail Corp. have signed a license agreement for Santhera’s JP-1730/fipamezole, granting Biovail U.S. and Canadian rights to develop and commercialize the drug for the treatment of dyskinesia in Parkinson’s Disease. In a recent Phase IIb study, JP-1730/ fipamezole showed the potential to reduce levodopa-induced dyskinesia. “Biovail is an emerging key player in the area of neurodegenerative disorders. With its commitment to this therapeutic area ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters